Long protocol of down regulation of ovaries was achieved by sub cutaneous administration of 1 mg of subcutaneous Buserelin Acetate (Suprefact
, Sanofi Aventis, Pakistan) in mid luteal phase of previous cycle.
After the patients were assessed for eligibility according to the mentioned criteria, a standard downregulation protocol was performed for all of them via a subcutaneous injection of GnRH agonists (0.5 mg of buserelin, Suprefact
, Serono), on day 21 of their menstrual cycle (1 wk before the expected menses).
All patients underwent conventional IVF/ICSI treatment with the standard long protocol using a GnRH agonist (Suprefact
, Hoechst, Frankfurt, Germany) for pituitary suppression.
After the initial work-up, controlled ovarian hyperstimulation (COH) was done with the long protocol: Gonadotropin-releasing hormone agonist (GnRH agonist; injection Suprefact
0.5cc) was started in the luteal phase (Day 21) of the preceding cycle; 150 IU of human menopausal gonadotropin (hMG) was started at day 3 of the cycle; and 10,000 international units (IU) of human chorionic gonadotropin (hCG) was given to trigger ovulation.
In addition, the brand of LHRH agonist (Lupron [Abbott Laboratories, Saint Laurent,QC], Zoladex [AstraZeneca Canada, Mississauga, ON], Suprefact
[sanofi-aventis, Laval, QC], Eligard [sanofi-aventis, Laval, QC], Trelstar [Watson Pharma Inc., Parsippany, NJ] was recorded.
However this tremendous discrepancy in price does not simply include basic pain relief, but also antibiotics such as Dalacin and Augmentin, cancer medication such as Casodex and Suprefact
, along with anti-depression medication such as Xanax and Lexotanil, among others.
), a mammalian GnRH analogue, was purchased from Aventis Pharma Ltd.
Follicles were aspirated under ultrasound-guided transvaginal puncture after pituitary desensitization with Buserilin nasal spray (800 [micro]g daily; Suprefact
, Hoechtst, Belgium) followed by human menopausal gonadotropin (hMG), only 2 ampules of 75 U daily until at least two follicles reached a diameter of 20 mm.
The downregulation protocol was used for all the patients via a subcutaneous injection of GnRH agonists (0.2 mg buserelin, Suprefact
, Serono, Rome, Italy), starting from the 21st day of the same cycle when melatonin was started.
1 mg of subcutaneous Buserelin Acetate (Suprefact
) was initiated on day 21 to achieve adequate ovarian suppression, followed by recombinant FSH (Gonal-f) or hMG (Menogon).
Down regulation and ovulation induction was performed by the administration of gonadotrophin-releasing hormone (GnRH) agonist (Suprefact
or Decapeptyl) together with gonadotrophins.